Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material

• Main Authors: José Antonio Lebrón, Francisco José Ostos, Manuel López-López, María Luisa Moyá, Carlos Sales, Encarnación García, Clara Beatriz García-Calderón, Margarita García-Calderón, María José Peña-Gómez, Iván V. Rosado, Fernando R. Balestra, Pablo Huertas, Pilar López-Cornejo
• Format: Article
• Language: English
• Published: MDPI AG 2020-05-01
• Series: Pharmaceutics
• Subjects: non-toxic nanocarriers; specificity by cancer cells; gene therapy; transfection process; metallo-liposomes; ruthenium(II)-based lipids
• Online Access: https://www.mdpi.com/1999-4923/12/5/482

Gene therapy is a therapeutic process consisting of the transport of genetic material into cells. The design and preparation of novel carriers to transport DNA is an important research line in the medical field. Hybrid compounds such as metallo-liposomes, containing a mixture of lipids, were prepared and characterized. Cationic metal lipids derived from the [Ru(bpy)₃]²⁺ complex, RuC11C11 or RuC19C19, both with different hydrophobic/lipophilic ratios, were mixed with the phospholipid DOPE. A relation between the size and the molar fraction α was found and a multidisciplinary study about the interaction between the metallo-liposomes and DNA was performed. The metallo-liposomes/DNA association was quantified and a relationship between K_app and α was obtained. Techniques such as AFM, SEM, zeta potential, dynamic light scattering and agarose gel electrophoresis demonstrated the formation of lipoplexes and showed the structure of the liposomes. L/D values corresponding to the polynucleotide’s condensation were estimated. In vitro assays proved the low cell toxicity of the metallo-liposomes, lower for normal cells than for cancer cell lines, and a good internalization into cells. The latter as well as the transfection measurements carried out with plasmid DNA pEGFP-C1 have demonstrated a good availability of the Ru(II)-based liposomes for being used as non-toxic nanovectors in gene therapy.